Navidea Biopharmaceuticals Announces Board Member Resignation

  Navidea Biopharmaceuticals Announces Board Member Resignation

            – Dr. Jess Jones Leaving Board for Personal Reasons –

Business Wire

DUBLIN, Ohio -- July 15, 2013

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that
Jess Emery Jones, MD, has resigned from his position as a member of Navidea’s
Board of Directors for personal reasons, effective July 9, 2013. Dr. Jones has
served on the Board of Directors since April 2011. The Company’s Compensation,
Nominating and Governance Committee expects to undertake a process in the near
future to evaluate Board composition.

“Jess has been an important member of the Navidea Board for the last few years
and played a strong hand in building our leadership in precision diagnostics,”
said Gordon Troup, Chairman, on behalf of Navidea’s Board of Directors. “We
will miss Jess’s participation in the Board room and wish him well in his
future endeavors.”

“Jess’s vision and leadership helped guide Navidea through a period of great
change and achievement," said Dr. Mark Pykett, Chief Executive Officer of
Navidea. "I have enjoyed working with Jess and will miss his counsel and
guidance.”

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.

Contact:

Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Executive VP & CFO
or
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
 
Press spacebar to pause and continue. Press esc to stop.